BioNexus Gene Lab Corp
BioNexus Gene Lab Corp (BGLC): 5 pipeline candidates · ~51 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
50.7 months
D/E 0.12 · 0% dilution
Lead: Preclinical
5 candidates
N/A
N/A
A transparent, data-derived signal for BioNexus Gene Lab Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.2M
Cash
$1.3M
Quarterly Burn
$148K
Runway
50.7 mo
Revenue
$23K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$2
| Holder | Shares | Value |
|---|---|---|
| wells fargo & company/mn | 1 | $2 |
Frequently asked questions
How many drug candidates are in BioNexus Gene Lab Corp's pipeline?
BioNexus Gene Lab Corp (BGLC) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BioNexus Gene Lab Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BioNexus Gene Lab Corp has approximately 50.7 months of cash runway.
What is BioNexus Gene Lab Corp's market capitalization?
BioNexus Gene Lab Corp's market capitalization is approximately $5.2M.
Who is the CEO of BioNexus Gene Lab Corp?
Mr. Su-Leng Tan is the chief executive officer of BioNexus Gene Lab Corp (BGLC).
Get the full picture on BioNexus Gene Lab Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.